Research News and Research

RSS

DYSlipidemia International Study results presented at the ESC congress

According to a new analysis of 22,000 patients, nearly three-quarters of patients taking statins still had at least one lipid abnormality. These results, from a study conducted by Merck & Co., Inc., Whitehouse Station, N.J., U.S.A., which operates in many countries as Merck Sharp & Dohme Limited, were presented today at the European Society of Cardiology (ESC) congress in Barcelona, Spain.

31 Aug 2009

IDRI signs agreement to use NanoPass' MicronJet microneedle technology for intradermal vaccines

The Infectious Disease Research Institute (IDRI) and NanoPass Technologies Ltd. (NanoPass) today announced they have entered into an agreement whereby IDRI licenses NanoPass' proprietary MicronJet microneedle technology for the intradermal delivery of products against a number of diseases including tuberculosis, HIV, malaria, leishmaniasis and leprosy, among others. The financial details of the agreement are confidential.

31 Aug 2009

First Edition: August 31, 2009

Today's headlines hint that summer's almost over, but the heat will still be on for health reform.

31 Aug 2009

Abbott introduces XIENCE PRIME Everolimus Eluting Coronary Stent System for global market

Abbott (NYSE: ABT) today announced at the European Society of Cardiology Congress the widespread availability of its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

31 Aug 2009

Research reveals the reason why some patients with Ewing's sarcoma do not respond to chemotherapy

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors with high levels of a protein known as GSTM4, which may suppress the effects of chemotherapy. The research is published online today in the journal Oncogene.

31 Aug 2009

Spinal implant developed by Sanfor Clinic neurosurgeon receives FDA market clearance

Sanford Health, a comprehensive health care provider in the Upper Midwest, announced today a spinal implant developed by Sanford Clinic Neurosurgeon, Wilson Asfora, MD, Sanford Clinic Neurosurgery & Spine, has received United States Food and Drug Administration (FDA) 510(k) market clearance as a lumbar intervertebral body fusion device.

31 Aug 2009

Albany College of Pharmacy and Health Sciences launches Vermont's first pharmacy program

Following nearly two years of planning, Albany College of Pharmacy and Health Sciences opened its Vermont Satellite Campus today, welcoming 70 students in the inaugural class. The campus, located in scenic Colchester, Vermont, is home to the only pharmacy program in the state.

31 Aug 2009

Findings reveal that Americans have grown increasingly confident to pay for healthcare services

A new report -- Thomson Reuters Healthcare Indexes(TM): Consumer Confidence -- found that consumer confidence related to healthcare expenditures increased 12 percent between March and July.

31 Aug 2009

Fitness and weight loss are the main reasons behind European runners

To honour its 60th anniversary this year, ASICS took its expertise in running to another level by conducting an unprecedented research into the mind of the runner. Executed by the research institute Synovate, ASICS' 'Reasons to Run' research asked more than 3,500 runners in seven European countries* to reveal the 'why?' behind their actions, making it the biggest study of its kind ever.

31 Aug 2009

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds of the composite primary endpoint of death, myocardial infarction, urgent revascularization or rescue GPIIb/IIIa use in 4 out of the 5 otamixaban tested doses, versus standard UFH/eptifibatide combination in [non-ST] ACS patients suitable for invasive strategy.

31 Aug 2009

Nuevolution partners with Novartis for drug research

Nuevolution A/S today announced that it has entered into a drug discovery collaboration with Novartis.

31 Aug 2009

New radiotherapy treatment devised for treating women with metastatic ovarian cancer

In the future, women with metastatic ovarian cancer could be treated with a radioactive substance that can seek and destroy tumour cells. An initial study in patients conducted jointly by the Sahlgrenska Academy at the University of Gothenburg and Sahlgrenska University Hospital has found that the treatment has no unwanted side-effects.

31 Aug 2009

Sectra signs six-year partnership agreement with Curato

Sectra, the market leader in Scandinavia for managing radiology images and patient information systems (RIS/PACS), and Norwegian company Curato, the Nordic region’s largest supplier of radiology examinations, have signed a six-year partnership agreement for Sectra’s products and services. The order value amounts to approximately SEK 100 million.

31 Aug 2009

Boston Scientific appoints Senior Vice President for its Cardiac Rhythm Management group

Boston Scientific Corporation (NYSE: BSX) today announced that Ken Stein, M.D., FACC, will join the Company as Senior Vice President and Associate Chief Medical Officer for its Cardiac Rhythm Management (CRM) group. Dr. Stein is currently the Associate Director of Clinical Cardiac Electrophysiology at Weill Cornell Medical Center and Associate Professor of Medicine at Cornell University.

31 Aug 2009

Study reveals that downregulation of IRF-8 gene causes gum diseases, arthritis and osteoporosis

Investigators at Hospital for Special Surgery, collaborating with researchers from other institutions, have contributed to the discovery that a gene called interferon regulator factor-8 (IRF-8) is involved in the development of diseases such as periodontitis (gum disease), rheumatoid arthritis and osteoporosis. The study, which will be published online August 30, ahead of print, in the journal Nature Medicine, could lead to new treatments in the future.

31 Aug 2009

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease.

31 Aug 2009

High incidence of HIV infection is found among South African gays

New research from UCSF examining HIV among men who have sex with men (MSM) in the township of Soweto in South Africa has found that a third of gay-identified men are infected with HIV.

31 Aug 2009

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Results of the landmark RE-LY(R) Trial (Randomized Evaluation of Long term anticoagulant therapy) demonstrate that atrial fibrillation (AF) patients taking PRADAX(R) (dabigatran etexilate) 150mg twice daily (BID) significantly reduced their risk of stroke and systemic embolism by 34 per cent (p less than 0.001) as compared to patients well-controlled on warfarin, without increasing the risk of major bleeding.

31 Aug 2009

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

Boehringer Ingelheim today announced data from the landmark RE-LY® study - the largest atrial fibrillation (AF) outcomes trial ever conducted (18,113 patients in 44 countries worldwide) - presented for the first time at the European Society of Cardiology Congress and published online in the New England Journal of Medicine. Results show that dabigatran etexilate 150mg BID significantly reduces the risk of stroke and systemic embolism by 34% (p<0.001) in patients with atrial fibrillation compared to well-controlled warfarin without increasing the risk of major bleeding.

31 Aug 2009

New sleep formula unveiled at USANA Health Sciences' 17th annual international convention

USANA Health Sciences, Inc. hosted thousands of independent Associates and guests from around the world this week for its 17th annual international convention in Salt Lake City.

30 Aug 2009

Research News and Research

DYSlipidemia International Study results presented at the ESC congress

IDRI signs agreement to use NanoPass' MicronJet microneedle technology for intradermal vaccines

First Edition: August 31, 2009

Abbott introduces XIENCE PRIME Everolimus Eluting Coronary Stent System for global market

Research reveals the reason why some patients with Ewing's sarcoma do not respond to chemotherapy

Spinal implant developed by Sanfor Clinic neurosurgeon receives FDA market clearance

Albany College of Pharmacy and Health Sciences launches Vermont's first pharmacy program

Findings reveal that Americans have grown increasingly confident to pay for healthcare services

Fitness and weight loss are the main reasons behind European runners

Results of the Phase II SEPIA-ACS1/ TIMI-42 study presented at the plenary session of the Annual European Society of Cardiology

Nuevolution partners with Novartis for drug research

New radiotherapy treatment devised for treating women with metastatic ovarian cancer

Sectra signs six-year partnership agreement with Curato

Boston Scientific appoints Senior Vice President for its Cardiac Rhythm Management group

Study reveals that downregulation of IRF-8 gene causes gum diseases, arthritis and osteoporosis

FDA approves the usage of Valcyte for preventing CMV disease in pediatric patients

High incidence of HIV infection is found among South African gays

RE-LY trial establishes effectiveness of PRADAX in reducing stroke risk in AF patients

Oral dabigatran etexilate reduces the risk of stroke and systemic embolism

New sleep formula unveiled at USANA Health Sciences' 17th annual international convention

Human iPSCs: A Full Guide to Advanced in Vitro Models and Applications eBook

Latest eBooks

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics